BioCentury

8:00 AM GMT, Dec 22, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Putting fibromyalgia to sleep

Two drugs are approved in the U.S. to treat fibromyalgia. But given the long list of symptoms associated with the disorder, Jazz Pharmaceuticals Inc. believes there is plenty of room for new drugs to help manage the pain and fatigue that characterize the disease. The company now has positive data in hand from its first Phase III trial of JZP-6, and anticipates it will complete enrollment in a second Phase III study by year end.

In 1990, the American College of Rheumatology developed criteria for diagnosing fibromyalgia

Read the full 869 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.